Antibody variable region genes (VH and VL) from a given antibody can be reformatted to encode a different constant region and other formats including Fab, scFv, IgM, nanobody, and bispecific molecules. Multiple species and isotypes are available, with the option of synthesizing the constant region of choice.
These expression constructs can be expressed in HEK293 and CHO cells followed by enrichment and purification. The molecule of choice can be rapidly produced at scales ranging from milligram to gram quantities. We also offer high throughput 96-block antibody productions to fit your antibody screening needs.
Click here to learn more about TunaCHO for high yield antibody production.
New – Intact Mass Spec Analysis for All Recombinant Antibody Productions
High resolution mass spectrometers have achieved significant resolving power for large molecules. At Curia, we apply this unparalleled analytical capability to all recombinant antibodies we produce for our clients to enhance the quality standard, for peace of mind.
Additional services, such as peptide mapping and PTM analysis, are also available.
New – in vitro Glyco Engineering (IVGE)
Glycosylation is a common type of post-translational modification that can significantly influence protein stability, biological activity, and pharmacokinetics of the final product. One way to manipulate glycosylation is through IVGE.
Curia is teaming up with Roche Custom Biotech to offer custom IVGE service designed to improve therapeutic protein productions. With a two-step reaction of galactosylation followed by sialyation, glycoforms can be enriched with known kinetics and predictable outcomes. Click here to learn more details: FAQs
Fact Sheet: Large Scale Antibody Production: Hybridoma or recombinant?
After successful identification of a unique hybridoma for your therapeutic or diagnostic program, you need toquickly generate gram quantities for further evaluation.
Proteomic sequencing and resurrection of a monoclonal antibody
While hybridoma sequencing has become a routine part of drug development workflows, there are few options for antibody primary sequence determination when the source hybridoma is unavailable.